EGFR and non-small cell lung carcinoma: Osimertinib cemented its status as the preferred first-line systemic therapeutic option for EGFR mutated (EGFRm) NSCLC following the publication, in 2018, of the FLAURA trial (ClinicalTrials.gov number NCT02296125) comparing osimertinib to the first-generation EGFR TKIs gefitinib or erlotinib in patients whose tumors harbored EGFR-exon 19 deletions/indels or EGFR-L858R [8].